Abstract
The design and synthesis of hydroxyethylamine isosteres as inhibitors of cathepsin D based on SAR data have been accomplished. A library of 96 of these hydroxyethylamine isosteres are described and many have proven to be very potent inhibitors of human cathepsin D activity as measured using a fluorometric assay technique, via peptide substrate Ac-Glu-Glu(Edans)-Lys-Pro-Ile-Cys-Phe-Phe-Arg-Leu-Gly-Lys(Methyl Red)-Glu-NH2. Compounds showing strongest inhibition of cathepsin D activity were those that contain a hydroxyethyl-N’-2- or N’-(4-chlorophenyl)piperazine moiety (IC50 values range from 0.55 to 8.5 nM), with N’-(2-pyrimidyl)piperizine (IC50 values range from 0.5 to 21.6 nM), with NN’- L-piperazinocolinamide (IC50 values range from 0.001 – 0.25 nM), or N-N’-L-piperazinocolin-N-methylamide (IC50 values range from 0.015 – 7.3 nM) .
Keywords: Aspartyl protease, Cathepsin D, Inhibitors, Hydroxyethylamine, Piperazine, Pipecolinate, Piperazinocolinate
Medicinal Chemistry
Title:New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Volume: 8 Issue: 6
Author(s): Rose M. McConnell, Kalyani Inapudi, Naveen Kadasala, Karthika Yarlagadda, Priya Velusamy, Matthew S. McConnell, Adam Green, Carol Trana, Kelley Sayyar and James S. McConnell
Affiliation:
Keywords: Aspartyl protease, Cathepsin D, Inhibitors, Hydroxyethylamine, Piperazine, Pipecolinate, Piperazinocolinate
Abstract: The design and synthesis of hydroxyethylamine isosteres as inhibitors of cathepsin D based on SAR data have been accomplished. A library of 96 of these hydroxyethylamine isosteres are described and many have proven to be very potent inhibitors of human cathepsin D activity as measured using a fluorometric assay technique, via peptide substrate Ac-Glu-Glu(Edans)-Lys-Pro-Ile-Cys-Phe-Phe-Arg-Leu-Gly-Lys(Methyl Red)-Glu-NH2. Compounds showing strongest inhibition of cathepsin D activity were those that contain a hydroxyethyl-N’-2- or N’-(4-chlorophenyl)piperazine moiety (IC50 values range from 0.55 to 8.5 nM), with N’-(2-pyrimidyl)piperizine (IC50 values range from 0.5 to 21.6 nM), with NN’- L-piperazinocolinamide (IC50 values range from 0.001 – 0.25 nM), or N-N’-L-piperazinocolin-N-methylamide (IC50 values range from 0.015 – 7.3 nM) .
Export Options
About this article
Cite this article as:
M. McConnell Rose, Inapudi Kalyani, Kadasala Naveen, Yarlagadda Karthika, Velusamy Priya, S. McConnell Matthew, Green Adam, Trana Carol, Sayyar Kelley and S. McConnell James, New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines, Medicinal Chemistry 2012; 8 (6) . https://dx.doi.org/10.2174/1573406411208061146
DOI https://dx.doi.org/10.2174/1573406411208061146 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Drug Therapy for Prostate Cancer: An Overview
Current Medicinal Chemistry - Anti-Cancer Agents Single Chemical Entity Legal Highs: Assessing the Risk for Long Term Harm
Current Drug Abuse Reviews Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry The Involvement of ERCC2/XPD and ERCC6/CSB Wild Type Alleles in Protection Against Aging and Cancer
Current Aging Science Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Multicolor-FISH Approaches for the Characterization of Human Chromosomes in Clinical Genetics and Tumor Cytogenetics
Current Genomics Mammalian Cell Competitions, Cell-in-Cell Phenomena and Their Biomedical Implications.
Current Molecular Medicine Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Recent Trends in Glycodendrimer Syntheses and Applications
Current Topics in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Adverse Drug Reactions in the Oral Cavity
Current Pharmaceutical Design Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Intractable Cancers: The Many Faces of Multidrug Resistance and the Many Targets it Presents for Therapeutic Attack
Current Drug Targets The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology